Retinitis pigmentosa and AMD may be the beneficiaries of a new tool for gene therapy that significantly increases gene delivery to cells in the retina. 

In news reports, including Science Daily, senior author Rajendra Kumar-Singh, PhD, associate professor of ophthalmology and adjunct associate professor of neuroscience at Tufts University School of Medicine (TUSM) and member of the genetics; neuroscience; and cell, molecular, and developmental biology program faculties at the Sackler School of Graduate Biomedical Sciences at Tufts said: For the first time, we have demonstrated an efficient way to transfer DNA into cells without using a virus, currently the most common means of DNA delivery. Many non-viral vectors for gene therapy have been developed but few, if any, work in post-mitotic tissues such as the retina and brain. Identifying effective carriers like PEG-POD brings us closer to gene therapy to protect the retinal cells from degeneration. The research is published in 

Articles

Retina

Retinitis pigmentosa and AMD may be the beneficiaries of a new tool for gene therapy that significantly increases gene delivery to cells in the retina.